

PI 1182460

REC'D 21 JUN 2004

PCT

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

June 16, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/456,302

FILING DATE: March 20, 2003

RELATED PCT APPLICATION NUMBER: PCT/US04/08457



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

M. Tarver

M. TARVER
Certifying Officer

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

03/20/03

16904 U.S. PTO

03-21-00356302-032003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0851-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EL 900977997 US

INVENTOR(S)						
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)		
Munirathnam K.		Chaguturu		West Windsor, NJ		
Victoria Y.		Wong		Enfield, CT		
Susan N.		Gilbey		Camden, ME		
<input checked="" type="checkbox"/> Additional inventors are being named on the <u>1</u> separately numbered sheets attached hereto						
TITLE OF THE INVENTION (500 characters max)						
Hemipteran Glutamate Decarboxylase						
Direct all correspondence to:						
<input type="checkbox"/> Customer Number		CORRESPONDENCE ADDRESS				
OR		Type Customer Number here				
<input checked="" type="checkbox"/> Firm or Individual Name		Patent Administrator				
Address		FMC Corporation				
Address		1735 Market Street				
City		Philadelphia				
Country		United States of America		State	PA	
		Telephone		215-299-6985	ZIP	19103
				Fax	215-299-6984	
ENCLOSED APPLICATION PARTS (check all that apply)						
<input checked="" type="checkbox"/> Specification Number of Pages		46		<input type="checkbox"/> CD(s), Number		
<input type="checkbox"/> Drawing(s) Number of Sheets				<input type="checkbox"/> Other (specify)		
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76				Exp. Mail Stmt; postcard		
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT						
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE AMOUNT (\$)		
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees				160.00		
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:		06-1440				
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.						
The invention was made by an agency of the United States Government or under a contract with an agency of the						
<input checked="" type="checkbox"/> No.						
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:						

Respectfully submitted,

SIGNATURE

Terence J. Bogle

Date

03/20/03

TYPED or PRINTED NAME Terence J. Bogle

TELEPHONE 215-299-6596

REGISTRATION NO.

(if appropriate)

Docket Number:

44,544

60301-USA-PROVI

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

PROVISIONAL APPLICATION COVER SHEET
Additional Page

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Docket Number 60301-USA-PROV1		
INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Ruihau	Chen	Kendall Park, NJ

Number 1 of 1

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Practitioner's Docket No. 60301-USA-PROV1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Munitrathnam K. Chaguturu; Victoria Y. Wong; Susan Gilbey;
Ruihua Chen

Application No.: to be assigned

Group No.:

Filed: 03/20/03

Examiner:

For: Hemipteran Glutamate Decarboxylase

Assistant Commissioner for Patents
Washington, D.C. 20231

EXPRESS MAIL CERTIFICATE

"Express Mail" label number EL900977997US
Date of Deposit 03/20/03

I hereby state that the following *attached* paper or fee

Provisional Application for Patent Cover Sheet (2 pgs.)
Specification (46 pgs.)
Postcard (1)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. section 1.10, on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Janet A. Afflick


Signature of person mailing paper or fee

HEMIPTERAN GLUTAMATE DECARBOXYLASEField of the Invention

5 The present invention relates to nucleotide sequences that are useful in agrochemical, veterinary or pharmaceutical fields. In particular, the invention relates to nucleotide sequences that encode or may be used to express amino acid sequences that are useful in the identification or development of compounds with (potential) activity as pesticides or as pharmaceuticals. Even more particularly, the invention also relates to the
10 amino acid sequences - such as proteins or polypeptides - that are encoded by, or that may be obtained by suitable expression of, the nucleotide sequences of the invention.

Background of the Invention

 Gamma amino-n-butyric acid ("GABA") plays an important role in inhibiting synaptic transmission in both vertebrate and invertebrate nervous systems. L-glutamate
15 decarboxylase ("GAD") is a rate limiting enzyme involved in the synthesis of GABA. Hence, interruption of the conversion GAD to GABA can result in various biological effects (W. Loscher, J. Neurochem., (1981), Vol. 36, No.4, pp. 1521-1527). As such, there is a desire to develop ways to target this enzyme as a means of identifying
biologically active compounds, including insecticides (Gammon et al., Sites of Action of
20 Neurotoxic Pesticides, (1987), Chapter 9, pp. 122-134).

 Mammalian GADs, in particular human and mouse GADs, have been cloned and found to be functional when expressed in *E. coli* and mammalian cells (Huang et al., Proc. Natl. Acad. Sci. U. S. A., (1990), 87(21), pp. 8491-8495; Yamashita et al., Biochem. Biophys. Res. Commun., (1993), 192(3), pp. 1347-52; W. Loscher, J. Neurochem., (1981),
25 Vol. 36, No.4, pp. 1521-1527; and Davis et al., Biochem. Biophys. Res. Commun., (2000), 267(3), pp. 777-782). Similarly, bacteria, for example, *E. coli*, *Clostridium perfringens*, and *Lactobacillus brevis*, and fungi, for example, *Neurospora crassa*, GADs have been cloned and expressed (Hao et al., Biochem. J., (1993), 293(3), pp. 735-738; De Biase et al., Biotechnol. Appl. Biochem., (1993), 18(2), pp. 139-142; De Biase et al., Protein
30 Expression Purif., (1996), 8(4), pp. 430-438; M. L. Fonda, Methods in Enzymology,

Chaguturu et al.
Docket No.: 60301-USA-PROVI

PATENT

(1985), Vol. 113, pp. 11-16; and Ueno et al., (1997), Biosci. Biotech. Biochem., 61 (7), pp. 1168-1171).

In 1979, the *Drosophila melanogaster* GAD was partial purified (Chude et al., J. Neurochem. (1979), Vol. 32, 1409-1415). Later on, the *Drosophila melanogaster* GAD
5 was cloned and found to be functional when expressed in oocytes and in mammalian cells (Jackson et al., J. Neurochem., (1990), 54(3), 1068-78; and Phillips et al., J. Neurochem., (1993), 61(4), 1291-301).

Summary of the Invention

One embodiment of the invention relates to nucleotide sequences that encode or
10 may be used to express amino acid sequences that are useful in the identification or development of compounds with (potential) activity as pesticides or as pharmaceuticals. These nucleotide sequences, including mutants and fragments thereof, which will be further described below, will also be referred to herein as "*nucleotide sequences of the invention*".

15 Another embodiment of the invention relates to the amino acid sequences - such as proteins or polypeptides - that are encoded by, or that may be obtained by suitable expression of, the nucleotide sequences of the invention. These amino acid sequences, including mutants and fragments thereof, which will be further described below, will also be referred to herein as "*amino acid sequences of the invention*".

20 Yet another embodiment of the invention relates to the use of the nucleotide sequences of the invention, preferably in the form of a suitable genetic construct as described below, in the transformation of host cells or host organisms, for example for the expression of the amino acid sequences of the invention. The invention also relates to host cells or host organisms that have been transformed with the nucleotide sequences of the
25 invention or that can express the amino acid sequences of the invention.

In still yet another embodiment, the invention relates to methods for the identification or development of compounds that can modulate and/or inhibit the biological activity of the amino acid sequences of the invention, in which the above mentioned nucleotide sequences, amino acid sequences, genetic constructs, host cells or

host organisms are used. Such methods, which will usually be in the form of an assay or screen, will also be further described below.

In yet another embodiment, the invention relates to compounds that can modulate the (biological activity of), or that can otherwise interact with, an amino acid sequence of the invention, either *in vitro* or preferably (also) *in vivo*. The invention also relates to
5 compositions that contain such compounds, and to the use of such compounds in the preparation of these compositions.

Definitions

10 Collectively, the nucleic acids of the present invention will be referred to herein as "*nucleic acids of the invention*". Also, where appropriate in the context of the further description of the invention below, the terms "*nucleotide sequence of the invention*" and "*nucleic acid of the invention*" may be considered essentially equivalent and essentially interchangeable.

15 Also, for the purposes of the present invention, a nucleic acid or amino acid sequence is considered to "*(in) essentially isolated (form)*" – for example, from its native biological source – when it has been separated from at least one other component (and in particular macromolecule) with which it is usually associated, such as another nucleic acid, another protein or polypeptide or another (polymeric) biological component. In
20 particular, a nucleic acid or amino acid sequence is considered "essentially isolated" when it has been purified at least 2-fold, in particular at least 10-fold, more in particular at least 100-fold, and up to 1000-fold or more.

Detailed Description of the Invention

The present invention was established from the finding that the amino acid
25 sequences of the invention can be used as (potential) "target(s)" for *in vitro* or *in vivo* interaction with chemical compounds and other factors (with the term "*target*" having its usual meaning in the art, provide for example the definition given in WO 98/06737). Consequently, compounds or factors that have been identified as interacting with the amino acid sequences of the invention (e.g. by the methods as described herein below)
30 may be useful as active agents in the agrochemical, veterinary or pharmaceutical fields.

Chaguturu et al.
Docket No.: 60301-USA-PROV1

PATENT

In one embodiment, the invention relates to a nucleic acid, preferably in (essentially) isolated form, which nucleic acid comprises a nucleotide sequence of the invention, and in particular the nucleotide sequence of SEQ ID NO: 1. The nucleotide sequence of SEQ ID NO: 1 was derived or isolated from the *Aphis gossypii* organism, in the manner as further described in the Experimental Part below.

Generally, the nucleotide sequences of the invention, when in the form of a nucleic acid, may be DNA or RNA, and may be single stranded or double stranded. For example, the nucleotide sequences of the invention may be genomic DNA, cDNA or synthetic DNA (such as DNA with a codon usage that has been specifically adapted for expression in the intended host cell or host organism, which may for instance be designed using suitable computer programs such as Oligo-4, available from National Biosciences, Inc. (Plymouth, MN) and Consensus-Degenerate Hybrid Oligonucleotide Primers Software (CODEHOP) from Henikoff et al. (*Nucleic Acids Research*, 26, 70, 1628-1635, 1998) available on line through the Fred Hutchinson Cancer Research Center. Thus, the nucleotide sequences of the invention may contain intron sequences, and also generally comprises different splice variants.

Yet another embodiment relates to a double stranded RNA molecule directed against a nucleotide sequence of the invention (one strand of which will usually comprise at least part of a nucleotide sequence of the invention). The invention also relates to genetic constructs that can be used to provide such double stranded RNA molecules (e.g. by suitable expression in a host cell or host organism, or for example in a bacterial strain such as *E.coli*). For such constructs, reference is made to Maniatis et al., *Molecular Cloning, a Laboratory Manual* (Cold Spring Harbor Press, 1989).

In a broader sense, the term "nucleotide sequence of the invention" also comprises:

- parts or fragments of the nucleotide sequence of SEQ ID NO: 1;
- (natural or synthetic) mutants, variants, alleles, analogs, orthologs (herein below collectively referred to as "mutants") of the nucleotide sequence of SEQ ID NO: 1, as further described below.
- parts or fragments of such (natural or synthetic) mutants;

- nucleotide fusions of the nucleotide sequence of SEQ ID NO: 1 (or a part or fragment thereof) with at least one further nucleotide sequence;
 - nucleotide fusions of (natural or synthetic) mutants (or a part or fragment thereof) with at least one further nucleotide sequence;
- 5 in which such mutants, parts, fragments or fusions are preferably as further described below.

The invention also comprises different splice variants of the above nucleotide sequences.

- 10 Preferably, a nucleotide sequence of the invention will have a length of at least 500 nucleotides, preferably at least 1,000 nucleotides, more preferably at least 2,000 nucleotides; and up to a length of at most 5,500 nucleotides, preferably at most 5,000 nucleotides, more preferably at most, 4,600 nucleotides.

- 15 Examples of parts or fragments of the nucleotide sequence of SEQ ID NO: 1; or a part or fragment of a (natural or synthetic) mutant thereof include, but are not limited to, 5' or 3' truncated nucleotide sequences, or sequences with an introduced in frame startcodon or stopcodon. Also, two or more such parts or fragments of one or more nucleotide sequences of the invention may be suitably combined (e.g. ligated in frame) to provide a further nucleotide sequence of the invention.

- 20 Preferably, any such parts or fragments will be such that they comprise at least one continuous stretch of at least 100 nucleotides, preferably at least 250 nucleotides, more preferably at least 500 nucleotides, even more preferably more than 1,000 nucleotides, of the nucleotide sequence of SEQ ID NO: 1.

- 25 Also, it is expected that - based upon the disclosure herein - the skilled person will be able to identify, derive or isolate natural "mutants" (as mentioned above) of the nucleotide sequence of SEQ ID NO: 1 from (other individuals of) the same species (for example from an individual of a different strain or line, including but not limited to mutant strains or lines). It is also expected that - based upon the disclosure herein - the skilled person will be able to provide or derive synthetic mutants (as defined hereinabove) of the nucleotide sequence of SEQ ID NO: 1.

In one specific embodiment, the mutant is such that it encodes the nucleotide sequence of SEQ ID NO: 1 or a part or fragment thereof.

Preferably, any mutants as described herein will have one or more, and preferably all, of the structural characteristics or conserved features referred to below for the
5 nucleotide sequences of SEQ ID NO: 1.

In particular, any mutants, parts or fragments as described herein may be such that they at least encode the active or catalytic site of the corresponding amino acid sequence of the invention and a binding domain of the corresponding amino acid sequence of the invention.

10 Also, any mutants, parts or fragments as described herein will preferably have a degree of "sequence identity", at the nucleotide level, with the nucleotide sequence of SEQ ID NO 1, of at least 75%, preferably at least 80%, more preferably at least 85%, and in particular more than 90%, and up to 95% or more.

Also, preferably, any mutants, parts or fragments of the nucleotide sequence of the
15 invention will be such that they encode an amino acid sequence which has a degree of "sequence identity", at the amino acid level, with the amino acid sequence of SEQ ID NO: 2, of at least 50%, preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, and in particular more than 90% and up to 95% or more, in which the percentage of "sequence identity" is calculated as described below.

20 For this purpose, the percentage of "sequence identity" between a given nucleotide sequence and the nucleotide sequence of SEQ ID NO: 1 may be calculated by dividing the number of nucleotides in the given nucleotide sequence that are identical to the nucleotide at the corresponding position in the nucleotide sequence of SEQ ID NO: 1 by the total number of nucleotides in the given nucleotide sequence and multiplying by 100%, in
25 which each deletion, insertion, substitution or addition of a nucleotide - compared to the sequence of SEQ ID NO:1 - is considered as a difference at a single nucleotide position.

Alternatively, computer programs for determining sequence identity are publicly available. A preferred computer program for determining sequence identity is the program in Geneworks v 2.5 (Intelligenetics Inc, Mountain View CA), which uses a progressive
30 alignment procedure similar to FASTA. Preferably the parameters used with the

Chaguturu et al.
Docket No.: 60301-USA-PROVI

PATENT

Geneworks program are: cost to open gap = 50, lengthen gap = 100, minimum diagonal length = 4, maximum diagonal offset = 125. Other computer program methods to determine identity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP, 5 BLASTN, FASTA (Atschul, S.F. et al., J. Molec. Biol. 215: 403-410 (1990)) and VectorNTI (InforMax Inc., Bethesda, MD). The BLAST X program is publicly available from NCBI (blast@ncbi.nlm.nih.gov) and other sources (BLAST Manual, Altschul et al., NCBI NLM NIH, Bethesda, MD 20894; Altschul et al., J. Mol. Biol. 215: 403-410 (1990)), Vector NTI Suite Version 6 available from Informax Inc. North Bethesda, MD.

10 Also, in a preferred aspect, any mutants, parts or fragments as described herein will encode proteins or polypeptides having biological activity that is essentially similar to the biological activity described above for the sequences of SEQ ID NO: 1, i.e. to a degree of at least 50%, preferably at least 75%, and up to 90%, as measured by standard assay techniques as described below.

15 Any mutants, parts or fragments as described herein are preferably such that they are capable of hybridizing with the nucleotide sequence of SEQ ID NO: 1, i.e. under conditions of "moderate stringency", and preferably under conditions of "high stringency". Such conditions will be clear to the skilled person, for example from the standard handbooks, such as Sambrook et al. and Ausubel et al., mentioned above, as well 20 as in EP 0 967 284, EP 1 085 089 or WO 00/55318.

It is also within the scope of the invention to use a fusion of a nucleotide sequence of the invention (as described above) with one or more further nucleotide sequence(s), including but not limited to one or more coding sequences, non-coding sequences or regulatory sequences. Preferably, in such fusions, the one or more further nucleotide 25 sequences are operably connected (as described below) to the nucleotide sequence of the invention (for example so that, when the further nucleotide sequence is a coding sequence, the nucleotide fusion encodes a protein fusion as described below).

In another embodiment, the invention relates to an antisense molecule against a nucleotide sequence of the invention.

The nucleic acids of the invention may also be in the form of a genetic construct, again as further described below. Genetic constructs of the invention will generally comprise at least one nucleotide sequence of the invention, optionally linked to one or more elements of genetic constructs known per se, as described below. Such genetic constructs may be DNA or RNA, and are preferably double-stranded DNA. The constructs may also be in a form suitable for transformation of the intended host cell or host organism, in a form suitable for integration into the genomic DNA of the intended host cell or in a form suitable independent replication, maintenance and inheritance in the intended host organism. For instance, the genetic construct may be in the form of a vector, such as for example a plasmid, cosmid, a yeast artificial chromosome ("YAC"), a viral vector or transposon. In particular, the vector may be an expression vector, i.e. a vector that can provide for expression *in vitro* or *in vivo* (e.g. in a suitable host cell or host organism as described below). An expression vector comprising a nucleotide sequence of the invention is also referred to herein as a recombinant expression vector. These constructs will also be referred to herein as "*genetic constructs of the invention*".

In a preferred embodiment, such a construct a recombinant expression vector which will comprise:

- a) the nucleotide sequence of the invention; operably connected to:
- b) one or more regulatory elements, such as a promoter and optionally a suitable terminator;
- and optionally also:
- c) one or more further elements of genetic constructs known per se; in which the terms "*regulatory element*", "*promoter*", "*terminator*", "*further elements*" and "*operably connected*" have the meanings indicated herein below.

As the one or more "further elements" referred to above, the genetic construct(s) of the invention may generally contain one or more suitable regulatory elements (such as a suitable promoter(s), enhancer(s), or terminator(s)), 3'- or 5'-untranslated region(s) ("UTR") sequences, leader sequences, selection markers, expression markers or reporter genes, or elements that may facilitate or increase (the efficiency of) transformation or integration. These and other suitable elements for such genetic constructs will be clear to

the skilled person, and may for instance depend upon the type of construct used, the intended host cell or host organism; the manner in which the nucleotide sequences of the invention of interest are to be expressed (e.g. via constitutive, transient or inducible expression); and the transformation technique to be used.

5 Preferably, in the genetic constructs of the invention, the one or more further elements are "*operably linked*" to the nucleotide sequence(s) of the invention or to each other, by which is generally meant that they are in a functional relationship with each other. For instance, a promoter is considered "*operably linked*" to a coding sequence if
10 said promoter is able to initiate or otherwise control or regulate the transcription or the expression of a coding sequence (in which said coding sequence should be understood as being "*under the control of*" said promoter)

Generally, when two nucleotide sequences are operably linked, they will be in the same orientation and usually also in the same reading frame. They will usually also be essentially contiguous, although this may also not be required.

15 Preferably, the optional further elements of the genetic construct(s) used in the invention are such that they are capable of providing their intended biological function in the intended host cell or host organism.

For instance, a promoter, enhancer or terminator should be "*operable*" in the intended host cell or host organism, by which is meant that (for example) said promoter
20 should be capable of initiating or otherwise controlling or regulating the transcription or the expression of a nucleotide sequence - e.g. a coding sequence - to which it is operably linked (as defined above).

Such a promoter may be a constitutive promoter or an inducible promoter, and may also be such that it (only) provides for expression in a specific stage of development of the
25 host cell or host organism, or such that it (only) provides for expression in a specific cell, tissue, organ or part of a multicellular host organism.

Some particularly preferred promoters include, but are not limited to, constitutive promoters, such as cytomegalovirus ("*CMV*"), Rous sarcoma virus ("*RSV*"), simian virus-40 ("*SV40*"), for example, pSVL SV40 Late Promoter Expression Vector (Pharmacia
30 Biotech Inc., Piscataway, NJ), or herpes simplex virus ("*HSV*") for expression in

Chaguturu et al.
Docket No.: 60301-USA-PROVI

PATENT

mammalian cells or insect constitutive promoters such as the immediate early baculovirus promoter described by Jarvis et al. *Methods in Molecular Biology* Vol. 39 *Baculovirus Expression Protocols* ed. C. Richardson. Hamana Press Inc., Totowa, NJ 1995 available in pIE vectors from Novagen (Novagen, Inc. Madison, WI) or insect inducible promoters such as the *Drosophila metallothionein* promoter described by Bunch et al. *Nucleic Acids Research*, Vol. 6, No. 3 1043-106, 1988 available in vectors from Invitrogen (Invitrogen Corporation, Carlsbad, CA).

A selection marker should be such that it allows - i.e. under appropriate selection conditions - host cells or host organisms that have been (successfully) transformed with the nucleotide sequence of the invention to be distinguished from host cells or organisms that have not been (successfully) transformed. Some preferred, but non-limiting examples of such markers are genes that provide resistance against antibiotics (such as geneticin or G-418 (GIBCO- BRL, Grand Island, NY), kanamycine or ampicilline), genes that provide for temperature resistance, or genes that allow the host cell or host organism to be maintained in the absence of certain factors, compounds or (food) components in the medium that are essential for survival of the non-transformed cells or organisms.

A leader sequence should be such that - in the intended host cell or host organism - it allows for the desired post-translational modifications or such that it directs the transcribed mRNA to a desired part or organelle of a cell such as a signal peptide. A leader sequence may also allow for secretion of the expression product from said cell. As such, the leader sequence may be any pro-, pre-, or prepro-sequence operable in the host cell or host organism, including, but not limited to, picornavirus leaders, potyvirus leaders, a human immunoglobulin heavy-chain binding protein ("BiP"), a tobacco mosaic virus leader ("TMV"), and a maize chlorotic mottle virus leader ("MCMV").

An expression marker or reporter gene should be such that - in the host cell or host organism - it allows for detection of the expression of (a gene or nucleotide sequence present on) the genetic construct. An expression marker may optionally also allow for the localization of the expressed product, e.g. in a specific part or organelle of a cell or in (a) specific cell(s), tissue(s), organ(s) or part(s) of a multicellular organism. Such reporter genes may also be expressed as a protein fusion with the amino acid sequence of the

Chaguturu et al.
Docket No.: 60301-USA-PROV1

PATENT

invention. Some preferred, but non-limiting examples include fluorescent proteins, such as GFP, antibody recognition proteins, for example, V5 epitope or poly Histidine available in vectors and antibodies supplied by Invitrogen, or purification affinity handles such as polyhistidine which allows for purification on nickel columns or dihydrofolate reductase
5 which allows for purification on methotrexate column, or markers which allow for selection of cells expressing the gene such as the *E. coli* beta-galactosidase gene.

For some non-limiting examples of the promoters, selection markers, leader sequences, expression markers and further elements that may be present or used in the genetic constructs of the invention - such as terminators, transcriptional or translational
10 enhancers or integration factors - reference is made to the general handbooks such as Sambrook et al. and Ausubel et al. mentioned above, to W.B. Wood et al., "*The nematode Caenorhabditis elegans*", Cold Spring Harbor Laboratory Press (1988) and D.L. Riddle et al., "*C. ELEGANS II*", Cold Spring Harbor Laboratory Press (1997); as well as to the examples that are given in WO 95/07463, WO 96/23810, WO 95/07463, WO 95/21191,
15 WO 97/11094, WO 97/42320, WO 98/06737, WO 98/21355, U.S. Patent 6,207,410, U.S. Patent 5,693,492 and EP 1 085 089. Other examples will be clear to the skilled person.

Another embodiment of the invention relates to a host cell or host organism that has been transformed or contains with a nucleotide sequence, with a nucleic acid or with a genetic construct of the invention. The invention also relates to a host cell or host
20 organism that expresses, or (at least) is capable of expressing (e.g. under suitable conditions), an amino acid sequence of the invention. Collectively, such host cells or host organisms will also be referred to herein as "*host cells or host organisms of the invention*".

The host cell may be any suitable (fungal, prokaryotic or eukaryotic) cell or cell line, for example:

- 25 - a bacterial strain, including but not limited to strains of *E. coli*, *Bacillus*, *Streptomyces* and *Pseudomonas*;
- a fungal cell, including but not limited to cells from species of *Aspergillus* and *Trichoderma*;
- a yeast cell, including but not limited to cells from species of *Kluyveromyces* or
30 *Saccharomyces*;

- an amphibian cell or cell line, such as *Xenopus* oocytes.

In one specific embodiment, which may particularly useful when the nucleotide sequences of the invention are (to be) used in the discovery and development of insecticidal compounds, the host cell may be an insect-derived cell or cell line, such as:

- 5 - cells or cell lines derived from *Lepidoptera*, including but not limited to *Spodoptera* SF9 and Sf21 cells,
- cells or cell lines derived from *Aphis* ;
- cells or cell lines derived from *Drosophila*, such as Schneider and Kc cells; and
- 10 - cells or cell lines derived from a pest species of interest (as mentioned below), such as from *Heliothis virescens*.

The host cell may also be a mammalian cell or cell line, including but not limited to CHO- and BHK-cells and human cells or cell lines such as HeK, HeLa and COS.

The host organism may be any suitable multicellular (vertebrate or invertebrate) organism, including but not limited to:

- 15 - a nematode, including but not limited to nematodes from the genus *Caenorhabditis*, such as *C. elegans*,
- an insect, including but not limited to species of *Aphis*, *Drosophila*, *Heliothis*, or a specific pest species of interest (such as those mentioned above);
- other well known model organisms, such as zebrafish;
- 20 - a mammal such as a rat or mouse;

Other suitable host cells or host organisms will be clear to the skilled person, for example from the handbooks and patent applications mentioned above.

It should be noted that when a nucleotide sequence of the invention is expressed in a multicellular organism, it may be expressed throughout the entire organism, or only in
25 one or more specific cells, tissues, organs or parts thereof, for example by expression under the control of a promoter that is specific for said cell(s), tissue(s), organ(s) or part(s).

The nucleotide sequence may also be expressed during only a specific stage of development or life cycle of the host cell or host organism, again for example by
30 expression under the control of a promoter that is specific for said stage of development or

life cycle. Also, as already mentioned above, said expression may be constitutive, transient or inducible.

Preferably, these host cells or host organisms are such that they express, or are (at least) capable of expressing (e.g. under suitable conditions), an amino acid sequence of the invention (and in case of a host organism: in at least one cell, part, tissue or organ thereof). The invention also includes further generations, progeny and offspring of the host cell or host organism of the invention, which may for instance be obtained by cell division or by sexual or asexual reproduction.

In yet another aspect, the invention relates to a nucleic acid, preferably in (essentially) isolated form, which nucleic acid encodes or can be used to express an amino acid sequence of the invention (as defined herein), and in particular the amino acid sequence of SEQ ID NO: 2.

The amino acid sequence of SEQ ID NO: 2 may be isolated from the species mentioned above, using any technique(s) for protein isolation and purification known to one skilled in the art. Alternatively, the amino acid sequence of SEQ ID NO: 2 may be obtained by suitable expression of a suitable nucleotide sequence - such as the nucleotide sequence of SEQ ID NO: 1 or a suitable mutant thereof - in an appropriate host cell or host organism, as further described below.

In another aspect, the invention relates to a protein or polypeptide, preferably in (essentially) isolated form, said protein or polypeptide comprising an amino acid sequence of the invention (as defined above), in particular the amino acid sequence of SEQ ID NO: 2.

In a broader sense, the term "*amino acid sequence of the invention*" also comprises:

- parts or fragments of the amino acid sequence of SEQ ID NO: 2;
- (natural or synthetic) mutants, variants, alleles, analogs, orthologs (herein below collectively referred to as "*analogs*") of the amino acid sequence of SEQ ID NO: 2;
- parts or fragments of such analogs;
- fusions of the amino acid sequence of SEQ ID NO: 2 (or a part or fragment thereof) with at least one further amino acid residue or sequence;

- fusions of the amino acid sequence of an analog (or a part or fragment thereof) with at least one further amino acid residue or sequence;

in which such mutants, parts, fragments or fusions are preferably as further described below.

- 5 The term "*amino acid sequence of the invention*" also comprises "immature" forms of the abovementioned amino acid sequences, such as a pre-, pro- or prepro-forms or fusions with suitable leader sequences. Also, the amino acid sequences of the invention may have been subjected to post-translational processing or be suitably glycosylated, depending upon the host cell or host organism used to express or produce said amino acid
10 sequence; or may be otherwise modified (e.g. by chemical techniques known per se in the art).

- Examples of parts or fragments of the amino acid sequence of SEQ ID NO: 2, or a part or fragment of a (natural or synthetic) analog thereof mutant thereof include, but are not limited to, N- and C- truncated amino acid sequence. Also, two or more parts or
15 fragments of one or more amino acid sequences of the invention may be suitably combined to provide an amino acid sequence of the invention.

- Preferably, an amino acid sequence of the invention has a length of at least 100 amino acids, preferably at least 250 amino acids, more preferably at least 500 amino acids; and up to a length of at most 2,000 amino acids, preferably at most 1,000 amino acids,
20 more preferably at most 750 amino acids.

- Preferably, any such parts or fragments will be such that they comprise at least one continuous stretch of at least 5 amino acids, preferably at least 10 amino acids, more preferably at least 20 amino acids, even more preferably more than 30 amino acids, of the amino acid sequence of SEQ ID NO: 2.

- 25 In particular, any parts or fragments as described herein are such that they (at least) comprise the active or catalytic site of the corresponding amino acid sequence of the invention or a binding domain of the corresponding amino acid sequence of the invention. As will be clear to the skilled person, such parts or fragments may find particular use in assay- and screening techniques (as generally described below) and (when said part or
30 fragment is provided in crystalline form) in X-ray crystallography.

Chaguturu et al.
Docket No.: 60301-USA-PROVI

PATENT

Also, it is expected that - based upon the disclosure herein - the skilled person will be able to identify, derive or isolate natural "analogs" (as mentioned above) of the amino acid sequence of SEQ ID NO: 2. Such mutants could be derived from (other individuals of) the same species (for example from an individual of a different strain or line, including
5 but not limited to mutant strains or lines); or from (individuals of) other species. For example, such analogs could be derived from the insect species mentioned above.

It is also expected that - based upon the disclosure herein - the skilled person will be able to provide or derive synthetic "analogs" (as mentioned above) of the amino sequence of SEQ ID NO: 2.

10 Preferably, any mutants as described herein will have one or more, and preferably all, of the structural characteristics or conserved features referred to below for the sequences of SEQ ID NO: 2.

Preferably, any analogs, parts or fragments as described herein will be such that they have a degree of "sequence identity", at the amino acid level, with the amino acid
15 sequence of SEQ ID NO: 2 of at least 50%, preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, and in particular more than 90% and up to 95 % or more.

For this purpose, the percentage of "sequence identity" between a given amino acid sequence and the amino acid sequence of SEQ ID NO: 2 may be calculated by dividing
20 the number of amino acid residues in the given amino acid sequence that are identical to the amino acid residue at the corresponding position in the amino acid sequence of SEQ ID NO: 2 by the total number of amino acid residues in the given amino acid sequence and multiplying by 100%, in which each deletion, insertion, substitution or addition of an amino acid residue - compared to the sequence of SEQ ID NO: 2 - is considered as a
25 difference at a single amino acid (position).

Alternatively, the degree of sequence identity may be calculated using a known computer program, such as those mentioned above.

Also, such sequence identity at the amino acid level may take into account so-called "conservative amino acid substitutions", which are well known in the art, for
30 example from GB-A-2 357 768, WO 98/49185, WO 00/46383 and WO 01/09300; and

(preferred) types or combinations of such substitutions may be selected on the basis of the pertinent teachings from the references mentioned in WO 98/49185.

Also, preferably, any analogs, parts or fragments as described herein will have a biological activity that is essentially similar to the biological activity described above for the sequences of SEQ ID NO: 2, i.e. to a degree of at least 10%, preferably at least 50% more preferably at least 75%, and up to 90%, as measured by standard assay techniques as described below.

It is also within the scope of the invention to use a fusion of an amino acid sequence of the invention (as described above) with one or more further amino acid sequences, for example to provide a protein fusion. Generally, such fusions may be obtained by suitable expression of a suitable nucleotide sequence of the invention - such as a suitable fusion of a nucleotide sequence of the invention with one or more further coding sequences - in an appropriate host cell or host organism, as further described below.

One particular embodiment, such fusions may comprise an amino acid sequence of the invention fused with a reporter protein such as glutathione S-transferase ("GST"), green fluorescent protein ("GFP"), luciferase or another fluorescent protein moiety. As will be clear to the skilled person, such fusions may find particular use in expression analysis and similar methodologies.

In another embodiment, the fusion partner may be an amino acid sequence or residue that may be used in purification of the expressed amino acid sequence, for example using affinity techniques directed against said sequence or residue. Thereafter, said sequence or residue may be removed (e.g. by chemical or enzymatical cleavage) to provide the nucleotide sequence of the invention (for this purpose, the sequence or residue may optionally be linked to the amino acid sequence of the invention via a cleavable linker sequence). Some preferred, but non-limiting examples of such residues are multiple histidine residues and glutathione residues.

In one preferred, but non-limiting aspect, any such fusion will have a biological activity that is essentially similar to the biological activity described above for the sequences of SEQ ID NO: 2, i.e. to a degree of at least 10%, preferably at least 50 % more

Chaguturu et al.
Docket No.: 60301-USA-PROV1

PATENT

preferably at least 75%, and up to 90%, as measured by standard assay techniques as described below.

The nucleotide sequences and amino acid sequences of the invention may generally be characterized by the presence of one or more of the following structural characteristics or conserved features:

For the gene *Aphis gossypii*: SEQ ID NO: 1 is a cDNA sequence encompassing the open reading frame; and SEQ ID NO: 2 is the protein encoded by SEQ ID NO: 1.

By analogy to other GADs, it is likely that the functional protein is monomeric. See, e.g., Hannan and Hall, In Comparative Molecular Neurobiology, Y. Pichon, 1993, Birkhuaser Verlag Basel Switzerland).

On the basis of the above, and although the invention is not specifically limited to any specific explanation or mechanism, the nucleotide sequences and amino acid sequences have (biological) activity as a decarboxylase. In particular, the present invention has shown activity as a decarboxylase from insects of the order *Hemiptera*, which are aphids, leafhoppers, whiteflies, scales and true bugs that have mouthparts adapted to piercing and sucking.

As is known in the art, biological activity of this kind can be measured using standard assay techniques (see I. Cozzani, Analytical Biochem., (1970), 33, pp. 125-131; Scriven et al., Analytical Biochem., (1988), 170, pp. 367-371; Holdiness et al., Analytical Letters, (1980), 13 (B15), pp. 1333-1344; Heerze et al., Analytical Biochem., (1990), 185, pp. 201-205; G. Zhang and A. W. Bown, *Phytochemistry*, (1997), Vol. 44, No. 6, pp. 1007-1009; O. Chude and J. Wu, *J. Neurochem.*, (1976), Vol. 27, pp. 83-86; Torchinskiy et al., *Doklady Akademii nauk SSR*, (1972), Vol. 205, No.3; and Rosenberg et al., *Analytical Biochem.*, (1989), 181, pp. 59-65).

Another embodiment of the invention relates to a nucleic acid probe that is capable of hybridizing with a nucleotide sequence of the invention under conditions of moderate stringency, preferably under conditions of high stringency, and in particular under stringent conditions (all as described above). Such nucleotide probes may for instance be used for detecting or isolating a nucleotide sequence of the invention or as a primer for amplifying a nucleotide sequence of the invention; all using techniques known per se, for

Chaguturu et al.
Docket No.: 60301-USA-PROV1

PATENT

which reference is again made to the general handbooks such as Sambrook et al. and Ausubel et al., mentioned above.

Preferably, when to be used for detecting or isolating another nucleotide sequence of the invention, such a nucleotide probe will usually have a length of between 15 and 100 nucleotides, and preferably between 20 and 80 nucleotides. When used as a primer for amplification, such a nucleotide probe will have a length of between 25 and 75 nucleotides, and preferably between 20 and 40 nucleotides.

Generally, such probes can be designed by the skilled person starting from a nucleotide sequence or amino acid sequence of the invention - and in particular the sequence of SEQ ID NO: 1 or SEQ ID NO: 2 - optionally using a suitable computer algorithm. Also, as will be clear to the skilled person, such probes may be degenerate probes.

In a further aspect, the invention relates to methods for preparing mutants and genetic constructs of the nucleotide sequences of the present invention.

Natural mutants of the nucleotide sequences of the present invention may be obtained in a manner essentially analogous to the method described in the Experimental Part, or alternatively by:

- construction of a DNA library from the species of interest in an appropriate expression vector system, followed by direct expression of the mutant sequence;
 - construction of a DNA library from the species of interest in an appropriate expression vector system, followed by screening of said library with a probe of the invention (as described below) or with a nucleotide sequence of the invention;
 - isolation of mRNA that encodes the mutant sequence from the species of interest, followed by cDNA synthesis using reverse transcriptase;
- or by any other suitable method(s) or technique(s) known per se, for which reference is for instance made to the standard handbooks, such as Sambrook et al., "Molecular Cloning: A Laboratory Manual" (2nd.ed.), Vols. 1-3, Cold Spring Harbor Laboratory Press (1989) and F. Ausubel et al., "Current protocols in molecular biology", Green Publishing and Wiley Interscience, New York (1987).

Techniques for generating such synthetic sequences of the nucleotide sequences of the present invention will be clear to the skilled person and may for instance include, but are not limited to, automated DNA synthesis; site-directed mutagenesis; combining two or more parts of one or more naturally occurring sequences, introduction of mutations that
 5 lead to the expression of a truncated expression product; introduction of one or more restriction sites (e.g. to create cassettes or regions that may easily be digested or ligated using suitable restriction enzymes), and the introduction of mutations by means of a PCR reaction using one or more "mismatched" primers, using for example a sequence of a naturally occurring GPCR as a template. These and other techniques will be clear to the
 10 skilled person, and reference is again made to the standard handbooks, such as Sambrook et al. and Ausubel et al., mentioned above.

The genetic constructs of the invention may generally be provided by suitably linking the nucleotide sequence(s) of the invention to the one or more further elements described above, for example using the techniques described in the general handbooks
 15 such as Sambrook et al. and Ausubel et al., mentioned above.

Often, the genetic constructs of the invention will be obtained by inserting a nucleotide sequence of the invention in a suitable (expression) vector known per se. Some preferred, but non-limiting examples of suitable expression vectors include:

- vectors for expression in mammalian cells: pSVL SV40 (Pharmacia), pMAMneo (Clontech), pcDNA3 (Invitrogen), pMC1neo (Stratagene), pSG5 (Stratagene), EBO-pSV2-neo (ATCC 37593), pBPV-1 (8-2) (ATCC 37110), pdBPV-MMTneo (342-12) (ATCC 37224), pRSVgpt (ATCC37199), pRSVneo (ATCC37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460) and 1ZD35 (ATCC 37565);
- vectors for expression in bacterial cells: pET vectors (Novagen) and pQE vectors (Qiagen);
- vectors for expression in yeast or other fungal cells: pYES2 (Invitrogen) and Pichia expression vectors (Invitrogen);
- vectors for expression in insect cells: pBlueBacII (Invitrogen), pE11 (Novagen), pMT/V5His (Invitrogen).

Chaguturu et al.
Docket No.: 60301-USA-PROV1

PATENT

5 In a further aspect, the invention relates to methods for transforming a host cell or a host organism with a nucleotide sequence, with a nucleic acid or with a genetic construct of the invention. The invention also relates to the use of a nucleotide sequence, of a nucleic acid or of a genetic construct of the invention transforming a host cell or a host organism.

10 According to one specific embodiment, the expression of a nucleotide sequence of the invention in a host cell or host organism may be reduced, compared to the original (e.g. native) host cell or host organism. This may for instance be achieved in a transient manner using antisense or RNA-interference techniques well known in the art, or in a constitutive manner using random, site specific or chemical mutagenesis of the nucleotide sequence of the invention.

15 Suitable transformation techniques will be clear to the skilled person and may depend on the intended host cell or host organism and the genetic construct to be used. Some preferred, but non-limiting examples of suitable techniques include ballistic transformation, (micro-)injection, transfection (e.g. using suitable transposons), electroporation and lipofection. For these and other suitable techniques, reference is again made to the handbooks and patent applications mentioned above.

20 After transformation, a step for detecting and selecting those host cells or host organisms that have been successfully transformed with the nucleotide sequence or genetic construct of the invention may be performed. This may for instance be a selection step based on a selectable marker present in the genetic construct of the invention or a step involving the detection of the amino acid sequence of the invention, e.g. using specific antibodies.

25 The transformed host cell (which may be in the form of a stable cell line) or host organisms (which may be in the form of a stable mutant line or strain) form further aspects of the present invention.

In yet another aspect, the invention relates to methods for producing an amino acid sequence of the invention.

30 To produce or obtain expression of the amino acid sequences of the invention, a transformed host cell or transformed host organism may generally be kept, maintained or

Chaguturu et al.
Docket No.: 60301-USA-PROV1

PATENT

cultured under conditions such that the (desired) amino acid sequence of the invention is expressed or produced. Suitable conditions will be clear to the skilled person and will usually depend upon the host cell or host organism used, as well as on the regulatory elements that control the expression of the (relevant) nucleotide sequence of the invention.

5 Again, reference is made to the handbooks and patent applications mentioned above in the paragraphs on the genetic constructs of the invention.

Generally, suitable conditions may include the use of a suitable medium, the presence of a suitable source of food or suitable nutrients, the use of a suitable temperature, and optionally the presence of a suitable inducing factor or compound (e.g.

10 when the nucleotide sequences of the invention are under the control of an inducible promoter); all of which may be selected by the skilled person. Again, under such conditions, the amino acid sequences of the invention may be expressed in a constitutive manner, in a transient manner, or only when suitably induced.

It will also be clear to the skilled person that the amino acid sequence of the

15 invention may (first) be generated in an immature form (as mentioned above), which may then be subjected to post-translational modification, depending on the host cell or host organism used. Also, the amino acid sequence of the invention may be glycosylated, again depending on the host cell or host organism used.

The amino acid sequences of the invention may then be isolated from the host cell

20 or host organism or from the medium in which said host cell or host organism was cultivated, using protein isolation and purification techniques known per se, such as (preparative) chromatography and electrophoresis techniques, differential precipitation techniques, affinity techniques (e.g. using a specific, cleavable amino acid sequence fused with the amino acid sequence of the invention) and preparative immunological techniques

25 (i.e. using antibodies against the amino acid sequence to be isolated).

In one embodiment, the amino acid sequence thus obtained may also be used to generate antibodies specifically against said sequence or an antigenic part or epitope thereof.

In one embodiment, the present invention relates to antibodies, for example

30 monoclonal and polyclonal antibodies, that are generated specifically against amino acid

sequences of the present invention, preferably SEQ ID NO: 2, or an analog, variant, allele, ortholog, part, fragment or epitope thereof.

Such antibodies, which form a further aspect of the invention, may be generated in a manner known per se, for example as described in GB-A-2 357 768, USA 5,693,492, 5 WO 95/32734, WO 96/23882, WO 98/02456, WO 98/41633 and WO 98/49306. Often, but not exclusively, such methods will involve as immunizing a immunocompetent host with the pertinent amino acid sequence of the invention or an immunogenic part thereof (such as a specific epitope), in amount(s) and according to a regimen such that antibodies against said amino acid sequence are raised, and than harvesting the antibodies thus generated, 10 e.g. from blood or serum derived from said host.

For instance, polyclonal antibodies can be obtained by immunizing a suitable host such as a goat, rabbit, sheep, rat, pig or mouse with (an epitope of) an amino acid sequence of the invention, optionally with the use of an immunogenic carrier (such as bovine serum albumin or keyhole limpet hemocyanin) or an adjuvant such as Freund's, saponin, aluminium 15 hydroxide or a similar mineral gel, or keyhole limpet hemocyanin or a similar surface active substance. After a suitable immune response has been raised (usually within 1-7 days), the antibodies can be isolated from blood or serum taken from the immunized animal in a manner known per se, which optionally may involve a step of screening for an antibody with desired properties (i.e. specificity) using known immunoassay techniques, for which 20 reference is again made to for instance WO 96/23882.

Monoclonal antibodies may for example be produced using continuous cell lines in culture, including hybridoma-based and similar techniques, again essentially as described in the above cited references. Accordingly, cells and cell lines that produce monoclonal antibodies against an amino acid sequence of the invention form a further aspect of the 25 invention, as do methods for producing antibodies against amino acid sequences of the invention, which methods may generally involve cultivating such a cell and isolating the antibodies from the culture or medium, again using techniques known per se.

Also, Fab-fragments against the amino acid sequences of the invention (such as F(ab)₂, Fab' and Fab fragments) may be obtained by digestion of an antibody with pepsin or 30 another protease, reducing disulfide-linkages and treatment with papain and a reducing agent,

Chaguturu et al.
Docket No.: 60301-USA-PROV1

PATENT

respectively. Fab-expression libraries may for instance be obtained by the method of Huse et al., 1989, Science 245:1275-1281.

5 In another embodiment, the amino acid sequence of the invention, or a host cell or host organism that expresses such an amino acid sequence, may also be used to identify or develop compounds or other factors that can modulate the (biological) activity of, or that can otherwise interact with, the amino acid sequences of the invention, and such uses form further aspects of the invention. As will be clear to the skilled person, in this context, the amino acid sequence of the invention will serve as a target for interaction with such a compound or factor.

10 In this context, the terms "*modulate*", "*modulation*", "*modulator*" and "*target*" will have their usual meaning in the art, for which reference is *inter alia* made to the definitions given in WO 98/06737. Generally, a modulator is a compound or factor that can enhance, inhibit or reduce or otherwise alter, influence or affect (collectively referred to as "*modulation*") a functional property of a biological activity or process (for example, 15 the biological activity of an amino acid sequence of the invention).

In this context, the amino acid sequence of the invention may serve as a target for modulation *in vitro* (e.g. as part of an assay or screen) or for modulation *in vivo* (e.g. for modulation by a compound or factor that is known to modulate the target, which compound or factor may for example be used as an active compound for agrochemical, 20 veterinary or pharmaceutical use).

For example, the amino acid sequences, host cells or host organisms of the invention may be used as part of an assay or screen that may be used to identify or develop modulators of the amino acid sequence of the invention, such as a primary screen (e.g. a screen used to identify modulators of the target from a set or library of test chemicals with 25 unknown activity with respect to the target) or a secondary assay (e.g. an assay used for validating hits from a primary screen or used in optimizing hit molecules, e.g. as part of hits-to-leads chemistry).

For instance, such an assay or screen may be configured as an *in vitro* assay or screen, which will generally involve binding of the compound or factor to be tested as a 30 potential modulator for the target (herein below also referred to as "test chemical") to the

target, upon which a signal generated by said binding is measured. Suitable techniques for such *in vitro* screening will be clear to the skilled person, and are for example described in Eldefrawi et al., (1987). FASEB J., Vol.1, pages 262-271 and Rauh et al., (1990), Trends in Pharmacol. Sci., vol.11, pages 325-329. For example, such an assay or screen may be
5 configured as a binding assay or screen, in which the test chemical is used to displace a detectable ligand from the target (e.g. a radioactive or fluorescent ligand), upon which the amount of ligand displaced from the target by the modulator is determined.

Such an assay or screen may also be configured as a cell-based assay or screen, in which a host cell of the invention is contacted with or exposed to a test chemical, upon
10 which at least one biological response by the host cell is measured.

Also, such an assay or screen may also be configured as an whole animal screen, in which a host organism of the invention is contacted with or exposed to a test chemical, upon which at least one biological response (such as a phenotypical, behavioral or physiological change, including but not limited to paralysis or death) by the host organism
15 is measured.

Thus, generally, the assays and screens described above will comprise at least one step in which the test chemical is contacted with the target (or with a host cell or host organism that expresses the target), and in particular in such a way that a signal is generated that is representative for the modulation of the target by the test chemical. In a
20 further step, said signal may then be detected.

Accordingly, in one aspect, the invention relates to a method for generating a signal that is representative for the interaction of an amino acid sequence of the invention with a test chemical, said method at least comprising the steps of:

- a) contacting the amino acid sequence of the invention, or a host cell or host organism
25 containing or expressing an amino acid sequence, with said test chemical, in such a way that a signal may be generated that is representative for the interaction between said test chemical and said amino acid sequence; and optionally
- b) detecting the signal that may thus be generated.

In another aspect, the invention relates to a method for identifying modulators and/or inhibitors of an amino acid sequence of the invention (e.g. from a set or library of test chemicals), said method at least comprising the steps of:

- 5 a) contacting the amino acid sequence of the invention, or a host cell or host organism containing or expressing an amino acid sequence, with a test chemical, in such a way that a signal may be generated that is representative for the interaction between said test chemical and said the target; and optionally
- b) detecting the signal that may thus be generated, said signal identifying the modulator and/or inhibitor of said amino acid sequence.

10 Accordingly, the present invention provides methods of identifying a modulator and/or inhibitor of a *hemipteran* GAD protein activity. In preferred embodiments, the *hemipteran* GAD protein used in the methods has an amino acid sequence selected from the group consisting of SEQ ID NO: 2, a mutant thereof, and a fragment thereof. In some
15 1. embodiments, the nucleic acid sequence that encodes the *hemipteran* GAD is SEQ ID NO:

A test chemical may be part of a set or library of compounds, which may be a diverse set or library or a focussed set or library, as will be clear to the skilled person. The libraries that may be used for such screening can be prepared using combinatorial chemical processes known in the art or conventional means for chemical synthesis.

20 The assays and screens of the invention may be carried out at medium throughput to high throughput, for example in an automated fashion using suitable robotics. In particular, in this embodiment, the method of the invention may be carried out by contacting the target with the test compound in a well of a multi-well plate, such as a standard 24, 96, 384, 1536 or 3456 well plate.

25 Usually, in a screen or assay of the invention, for each measurement, the target or host cell or host organism will be contacted with only a single test compound. However, it is also within the scope of the invention to contact the target with two or more test compounds - either simultaneously or sequentially - for example to determine whether said combination provides a synergistic effect.

Once a test chemical has been identified as a modulator and/or inhibitor for an amino acid sequence of the invention (e.g. by means of a screen or assay as described hereinabove), it may be used per se as a modulator and/or inhibitor of the relevant amino acid sequence of the invention, preferably, an amino acid sequence of SEQ ID NO: 2, a mutant thereof, and a fragment thereof, more preferably SEQ ID NO: 2 (e.g. as an active substance for agrochemical, veterinary or pharmaceutical use), or it may optionally be further optimized for final use, e.g. to improve properties such as solubility, adsorption, bio-availability, toxicity, stability, persistence, environmental impact, etc.. It will be clear to the skilled person that the nucleotide sequences, preferably SEQ ID NO: 1, amino acid sequences, host cells or host organisms and methods of the invention may find further use in such optimization methodology, for example as (part of) secondary assays.

The invention is not particularly limited to any specific manner or mechanism in or via which the modulator and/or inhibitor (e.g. the test chemical, compound or factor) modulates, inhibits, or interacts with, the target (*in vivo* or *in vitro*). For example, the modulator and/or inhibitor may be an agonist, an antagonist, an inverse agonist, a partial agonist, a competitive inhibitor, a non-competitive inhibitor, a cofactor, an allosteric inhibitor or other allosteric factor for the target, or may be a compound or factor that enhances or reduces binding of target to another biological component associated with its (biological) activity, such as another protein or polypeptide, a receptor, or a part of organelle of a cell. As such, the modulator and/or inhibitor may bind with the target (at the active site, at an allosteric site, at a binding domain or at another site on the target, e.g. covalently or via hydrogen bonding), block and/or inhibit the active site of the target (in a reversible, irreversible or competitive manner), block and/or inhibit a binding domain of the target (in a reversible, irreversible or competitive manner), or influence or change the conformation of the target.

As such, the test chemical, modulator and/or inhibitor may for instance be:

- an analog of a known substrate of the target;
- an oligopeptide, e.g. comprising between 2 and 20, preferably between 3 and 15 amino acid residues;
- an antisense or double stranded RNA molecule;

Chaguturu et al.
Docket No.: 60301-USA-PROVI

PATENT

- a protein, polypeptide;
- a cofactor or an analog of a cofactor.

The test chemical, modulator and/or inhibitor may also be a reference compound or factor, which may be a compound that is known to modulate, inhibit or otherwise interact with the target (e.g. a known substrate or inhibitor for the target) or a compound or factor that is generally known to modulate, inhibit or otherwise interact with other members from the general class to which the target belongs (e.g. a known substrate or inhibitor of said class).

Preferably, however, the test chemical, modulator and/or inhibitor is a small molecule, by which is meant a molecular entity with a molecular weight of less than 1,500, preferably less than 1,000. This may for example be an organic, inorganic or organometallic molecule, which may also be in the form of a suitable salt, such as a water-soluble salt. The term "small molecule" also covers complexes, chelates and similar molecular entities, as long as their (total) molecular weight is in the range indicated above.

As already mentioned above, the compounds or factors that have been identified or developed as modulators and/or inhibitors of the amino acid sequences of the invention, preferably, an amino acid sequence of SEQ ID NO: 2, a mutant thereof, and a fragment thereof, more preferably SEQ ID NO: 2, (and precursors for such compounds) may be useful as active substances in the agrochemical, veterinary or pharmaceutical fields, for example in the preparation of agrochemical, veterinary or pharmaceutical compositions, and both such modulators as well as compositions containing them further aspects of the invention.

For example, in the agrochemical field, the modulators and/or inhibitors of the invention may be used as an insecticide, nematocide, molluscicide, helminthicide, acaricide or other types of pesticides or biocides, e.g. to prevent or control (infestations with) harmful organisms, both as contact agents and as systemic agents. As such, the modulators and/or inhibitors may for example be used as a crop protection agent, as a pesticide for household use, or as an agent to prevent or treat damage caused by harmful organisms (e.g. for the protection of seed, wood or stored crops or fruits). Preferably, the modulators and/or inhibitors of the invention are used as insecticides.

For any such application, one or more modulators and/or inhibitors of the invention may be suitably combined with one or more agronomically acceptable carriers, adjuvants or diluents - and optionally also with one or more further compounds known per se with activity as (for example) a plant protection agent (to broaden the spectrum of action and optionally to provide a synergistic effect), herbicide, fertilizer or plant growth regulator - to provide a formulation suitable for the intended final use. Such a formulation may for example be in the form of a solution, emulsion, dispersion, concentrate, aerosol, spray, powder, flowable, dust, granule, pellet, fumigation candle, bait or other suitable solid, semi-solid or liquid formulation, and may optionally also contain suitable solvents, emulsifiers, stabilizers, surfactants, antifoam agents, wetting agents, spreading agents, sticking agents, attractants or (for a bait) food components. Reference is made to the standard manuals, such as "Pesticidal Formulation Research", ACS-publications (1969) and "Pesticide Formulations", Wade van Valkenburg Ed, Marcel Dekker publications (1973).

Such compositions may generally contain one or more modulators and/or inhibitors of the invention in a suitable amount, which generally may be between 0.1 and 99 %, and in particular between 10 and 50 %, by weight of the total composition.

The modulators and/or inhibitors and compositions of the invention may be particularly useful as insecticides, for example to combat or control undesired or harmful insects (both adult and immature forms, such as larvae) from following orders:

- *Coleoptera*, such as *Pissodes strobi*, *Diabrotica undecimpunctata howardi*, and *Leptinotarsa decemlineata*;
- *Diptera*, such as *Rhagoletis pomonella*, *Mayetiola destructor*, and *Liriomyza huidobrensis*;
- *Hymenoptera*, such as *Neodiprion taedae tsugae*, *Camponotus pennsylvanicus*, and *Solenopsis wagneri*;
- *Hemiptera*, such as *Pseudatomoscelis seriatus*, *Lygus lineolaris* (Palisot de Beauvois), *Acrosternum hilare*, and *Aphis gossypii*
- *Homoptera*; and
- *Lepidoptera* such as *Heliothis virescens*.

When used to control harmful or undesired organisms, these organisms may be directly contacted with the modulators, inhibitors, or compositions of the invention in an amount suitable to control (e.g. kill or paralyze) the organism. This amount may be readily determined by the skilled person (e.g. by testing the compound on the species to be controlled) and will usually be in the region of between particular between 10 and 500 g/ha, in particular between 100 and 250 g/ha.

The modulators, inhibitors, or compositions of the invention may also be applied systemically (e.g. to the habitat of the organism to be controlled or to the soil), and may also be applied to the plant, seed, fruit etc. to be protected, again in suitable amounts, which can be determined by the skilled person. The modulators and/or inhibitors of the invention may also be incorporated - e.g. as additives - in other compositions known per se, for example to replace other pesticidal compounds normally used in such compositions.

In one specific embodiment, the modulators and/or inhibitors and compositions of the invention may be used in the fields of agrochemical, veterinary or human health to prevent or treat infection or damage or discomfort caused by parasitic organisms, and in particular by parasitic arthropods, nematodes and helminths such as:

- ectoparasitic arthropods such as ticks, mites, fleas, lice, stable flies, horn flies, blowflies and other biting or sucking ectoparasites;
 - endoparasites organisms such as helminths;
- and also to prevent or treat diseases that are caused or transferred by such parasites. For such purposes, the modulators and/or inhibitors of the invention may for example be formulated as a tablet, an oral solution or emulsion, an injectable solution or emulsion, a lotion, an aerosol, a spray, a powder, a dip or a concentrate.

In the fields of animal and human health, the modulators, inhibitors, and compositions of the invention may also be used for the prevention or treatment of diseases or disorders in which the amino acid sequence of the invention may be involved as a target. For this purpose, the modulators and/or inhibitors of the invention may be formulated with one or more additives, carriers or diluents acceptable for pharmaceutical or veterinary use, which will be clear to the skilled person.

Chaguturu et al.
Docket No.: 60301-USA-PROV1

PATENT

Thus, in a further aspect, the invention relates to the use of a modulator and/or inhibitor of the invention in the preparation of a composition for agrochemical, veterinary or pharmaceutical use, as described hereinabove. The invention relates to the use of the modulators, inhibitors and compositions of the invention in controlling harmful organisms and in preventing infestation or damage caused by harmful organisms, again as described above.

The invention will now be further illustrated by means of the following non-limiting Experimental Part.

10 Experimental Part:

Example 1. Cloning of Cotton Aphid ("CA") glutamate decarboxylase

15 **1. Isolation of poly(A⁺) RNA.**

CA polyA RNA isolation. A 0.1% solution of diethyl pyrocarbonate ("DEPC" available from Aldrich Chemical Co., Inc. Milwaukee, WI) in water was incubated at ambient temperature for about 16 hours and then autoclaved for 60 minutes. All glassware was baked for six hours at 180°C and all bottle caps were soaked in the 0.1% DEPC solution prior to use. The microprobe of a Braun homogenizer (available from B. Braun Biotech International, Allentown, PA) was soaked in 50 mls of 100% ethanol ("EtOH", available from J.T. Baker Inc., Phillipsburg, NJ) and then dried air-dried at ambient temperature. Cotton aphids were collected from cotton plants and placed on ice in tared centrifuge tubes. After harvesting approximately 1.2 grams of material, the cotton aphids were frozen at -70°C until use. The aphids (1.0 gram) were then weighed out into two 0.4 gram aliquots. The 0.4 gram aliquots were then taken up in 1.5 mls of Elution Buffer from a QuickPrep™ mRNA Purification kit (herein referred to as "PK", available from Amersham Pharmacia biotech, Piscataway, NJ), which was chilled in an ice bath prior to use. The resulting solution was homogenized at full speed and ambient temperature to form a uniform suspension. An additional 1.5 mls of the chilled Elution Buffer was added and the resulting solution was homogenized at full speed and ambient temperature for thirty

seconds. The resulting macerate was clarified by centrifugation at 12000g in an SS34 rotor (available from Sorvall Products, L.P, Asheville, NC) for 10 minutes at ambient temperature. Upon completion of this period, the supernatant was processed on a oligo(dT)-cellulose spun column from the PK. The column was washed with high salt and low salt buffers from the PK followed by three 0.25 mL portions of Elution Buffer from the PK, which was warmed to 65°C prior to use, as specified by the PK. A 0.5 mL portion of the elute was separated and 50 µl of a potassium acetate solution from the PK, 10 µl of a glycogen solution from the PK, and 1 ml of a 95% aqueous ethanol were added. The resulting mixture was stored at 20°C for one hour. After this time, the resulting mixture was centrifuged at _____ and ambient temperature for _____ in the SS34 rotor. The resulting precipitate was taken up in 50 µl of the 0.1% DEPC solution disclosed above. Five hundred µgs of total RNA were used to isolate polyA mRNA following the protocol of the QuickPrep™ mRNA Purification kit. The concentration of polyA mRNA was measured by UV spectrometry. The aphid polyA mRNA solution was stored at -80°C for future use.

Reverse Transcription and PCR amplification. Reverse transcription and PCR amplification (herein after referred to as "RT-PCR") was accomplished using a Titanium™ One-Step RT-PCR kit (available from Invitrogen Corp., Carlsbad, CA). A 50 µl RT-PCR reaction was prepared according to the manufacturer's instructions. The RT-PCR reaction included the following: 43.5 µl of a RT-PCR Master Mix prepared according to the manufacturer's instructions, 2 µl of polyA RNA, 3.5 µl of the 0.1% DEPC solution described above, and 0.5 µl of gene specific primers. The reactions were initially placed on a Geneamp 9700 thermal cycler (available from Perkin-Elmer-ABI, Foster City, CA) and held for 60 minutes at 50°C followed by five minutes at 94°C. After this time, the RT-PCR reaction was held for thirty seconds at 94°C followed by thirty seconds at 65°C and finally one minute at 68°C. After secondary "nested" amplifications were carried out in the manner described above, the resulting PCR products were incubated at 68°C for two minutes.

Chaguturu et al.
Docket No.: 60301-USA-PROVI

PATENT

Subcloning and sequencing. PCR products were subcloned into a pCR2.1-TOPO vector using a TOPO TA Cloning kit (available from Invitrogen Corp.) according to the manufacturer's instructions. The resulting pCR2.1-TOPO vector was sequenced and then analyzed using VectorNTI suite 6.0 software.

5

Primers. The primers utilized were as follows:

Primer	Sequence	Translation	Orientation

Chaguturu et al.
Docket No.: 60301-USA-PROV1

PATENT

CLAIMS:

1. A substantially pure protein having the amino acid sequence selected from the group consisting of: SEQ ID NO: 2, a mutant thereof, and a fragment thereof.
- 5 2. The protein of claim 1 wherein said protein has the amino acid sequence of SEQ ID NO: 2.
3. An isolated nucleic acid molecule that comprises a nucleic acid sequence that encodes the protein of claim 1.
- 10 4. A recombinant expression vector comprising the nucleic acid molecule of claim 3.
5. A host cell comprising the recombinant expression vector of claim 4.
- 15 6. An isolated nucleic acid molecule that comprises a nucleic acid sequence that encodes the protein of claim 2.
7. A recombinant expression vector comprising the nucleic acid molecule of claim 6.
- 20 8. A host cell comprising the recombinant expression vector of claim 7.
9. An isolated nucleic acid molecule consisting of SEQ ID NO: 1 or a fragment thereof having at least 10 nucleotides.
- 25 10. The nucleic acid molecule of claim 9 consisting of SEQ ID NO: 1.

Chaguturu et al.
Docket No.: 60301-USA-PROV1

PATENT

11. A recombinant expression vector comprising the nucleic acid molecule of claim 10.
12. A host cell comprising the recombinant expression vector of claim 11.
- 5 13. The nucleic acid molecule of claim 9 consisting of a fragment of SEQ ID NO: 1 having at least 10 nucleotides.
- 10 14. The nucleic acid molecule of claim 9 consisting of a fragment of SEQ ID NO: 1 having 12-150 nucleotides.
- 15 15. The nucleic acid molecule of claim 9 consisting of a fragment of SEQ ID NO: 1 having 15-50 nucleotides.
16. An isolated antibody which binds to an epitope on SEQ ID NO: 2.
17. The antibody of claim 16 wherein said antibody is a monoclonal antibody.
18. A method of preparing an isolated protein having the amino acid sequence selected from the group consisting of SEQ ID NO: 2, a mutant thereof, and a fragment thereof comprising the step of isolating said protein from a host cell of claim 5.
- 20 19. A modulator of a protein identified or developed using a substantially pure form of the protein, wherein said protein has an amino acid sequence selected from the group consisting of: SEQ ID NO: 2, a mutant thereof, and a fragment thereof.
- 25 20. The modulator according to claim 19, wherein the modulator is an insecticide.

Chaguturu et al.
Docket No.: 60301-USA-PROVI

PATENT

21. A modulator of a protein identified or developed using a substantially pure form of the protein, wherein said protein has an amino acid sequence of SEQ ID NO: 2.
22. The modulator according to claim 21, wherein the modulator is an insecticide.
23. A modulator of a protein identified or developed using the isolated nucleic acid molecule of claim 3, wherein said protein has an amino acid sequence selected from the group consisting of: SEQ ID NO: 2, a mutant thereof, and a fragment thereof.
24. The modulator according to claim 23, wherein the modulator is an insecticide.
25. A modulator of a protein identified or developed using the recombinant expression vector of claim 4, wherein said protein has an amino acid sequence selected from the group consisting of: SEQ ID NO: 2, a mutant thereof, and a fragment thereof.
26. The modulator according to claim 25, wherein the modulator is an insecticide.
27. A modulator of a protein identified or developed using the host cell of claim 5, wherein said protein has an amino acid sequence selected from the group consisting of: SEQ ID NO: 2, a mutant thereof, and a fragment thereof.
28. The modulator according to claim 27, wherein the modulator is an insecticide.
29. A modulator of a protein identified or developed using the isolated nucleic acid molecule of claim 6, wherein said protein has an amino acid sequence of SEQ ID NO: 2.
30. The modulator according to claim 29, wherein the modulator is an insecticide.
31. A modulator of a protein identified or developed using the recombinant expression vector of claim 7, wherein said protein has an amino acid sequence of SEQ ID NO: 2.

Chaguturu et al.
Docket No.: 60301-USA-PROVI

PATENT

32. The modulator according to 31, wherein the modulator is an insecticide.
33. A modulator of a protein identified or developed using the host cell of claim 8,
5 wherein said protein has an amino acid sequence of SEQ ID NO: 2.
34. The modulator according to claim 33, wherein the modulator is an insecticide.
35. A modulator of a protein identified or developed using the isolated nucleic acid
10 molecule of claim 9, wherein said protein has an amino acid sequence selected from the
group consisting of: SEQ ID NO: 2, a mutant thereof, and a fragment thereof.
36. The modulator according to claim 35, wherein the modulator is an insecticide.
- 15 37. A modulator of a protein identified or developed using the nucleic acid molecule of
claim 10, wherein said protein has an amino acid sequence selected from the group
consisting of: SEQ ID NO: 2, a mutant thereof, and a fragment thereof.
- 20 38. The modulator according to claim 37, wherein the modulator is an insecticide.
39. A modulator of a protein identified or developed using the recombinant expression
vector of claim 11, wherein said protein has an amino acid sequence selected from the
group consisting of: SEQ ID NO: 2, a mutant thereof, and a fragment thereof.
- 25 40. The modulator according to claim 39, wherein the modulator is an insecticide.
41. A modulator of a protein identified or developed using the host cell of claim 12,
wherein said protein has an amino acid sequence selected from the group consisting of:
SEQ ID NO: 2, a mutant thereof, and a fragment thereof.
- 30

Chaguturu et al.
Docket No.: 60301-USA-PROVI

PATENT

42. The modulator according to claim 41, wherein the modulator is an insecticide.
43. A modulator of a protein identified or developed using the nucleic acid molecule of claim 13, wherein said protein has an amino acid sequence selected from the group
5 consisting of: SEQ ID NO: 2, a mutant thereof, and a fragment thereof.
44. The modulator according to claim 43, wherein the modulator is an insecticide.
45. A modulator of a protein identified or developed using the nucleic acid molecule of
10 claim 14, wherein said protein has an amino acid sequence selected from the group consisting of: SEQ ID NO: 2, a mutant thereof, and a fragment thereof.
46. The modulator according to claim 45, wherein the modulator is an insecticide.
- 15 47. A modulator of a protein identified or developed using the nucleic acid molecule of claim 15, wherein said protein has an amino acid sequence selected from the group consisting of: SEQ ID NO. 2, a mutant thereof, and a fragment thereof.
- 20 48. The modulator according to claim 47, wherein the modulator is an insecticide.
49. A modulator of a *hemipteran* L-glutamate decarboxylase protein identified or developed using a method of identifying said modulator of said *hemipteran* L-glutamate decarboxylase protein activity, wherein said *hemipteran* L-glutamate decarboxylase protein has an amino acid sequence selected from the group consisting of: SEQ ID NO. 2,
25 a mutant thereof, and a fragment thereof; and said method comprises the steps of:
- a) contacting the amino acid sequence, or a host cell or host organism containing or expressing the amino acid sequence, with a test chemical, in such a way that a signal may be generated that is representative for the interaction between said test chemical and said the target; and optionally

- b) detecting the signal that may thus be generated, said signal identifying the modulator of said amino acid sequence.

50. The modulator according to claim 49, wherein the modulator is an insecticide.

5

51. The modulator according to claim 49, wherein said *hemipteran* L-glutamate decarboxylase protein has an amino acid sequence of: SEQ ID NO: 2.

52. The modulator according to claim 51, wherein a nucleic acid sequence that encodes said *hemipteran* L-glutamate decarboxylase is SEQ ID NO: 1.

10

53. An inhibitor of a *hemipteran* L-glutamate decarboxylase protein identified or developed using a method of identifying said inhibitor of said *hemipteran* L-glutamate decarboxylase protein activity, wherein said *hemipteran* L-glutamate decarboxylase protein has an amino acid sequence selected from the group consisting of: SEQ ID NO. 2, a mutant thereof, and a fragment thereof; and said method comprises the steps of:

15

- a) contacting the amino acid sequence, or a host cell or host organism containing or expressing the amino acid sequence, with a test chemical, in such a way that a signal may be generated that is representative for the interaction between said test chemical and said the target; and optionally
- b) detecting the signal that may thus be generated, said signal identifying the inhibitor of said amino acid sequence.

20

54. The inhibitor according to claim 53, wherein the modulator is an insecticide.

25

55. The inhibitor according to claim 53, wherein said *hemipteran* L-glutamate decarboxylase protein has an amino acid sequence of: SEQ ID NO: 2.

56. The inhibitor according to claim 55, wherein a nucleic acid sequence that encodes said *hemipteran* L-glutamate decarboxylase is SEQ ID NO: 1.

30

Chaguturu et al.
Docket No.: 60301-USA-PROV1

PATENT

57. A method of controlling an insect, comprising contacting an insect with a modulator identified by a method of identifying said modulator, wherein said method comprises the steps of:

- 5 a) contacting an amino acid sequence, or a host cell or host organism containing or expressing the amino acid sequence, with a test chemical, in such a way that a signal may be generated that is representative for the interaction between said test chemical and said the target; and optionally
- 10 b) detecting the signal that may thus be generated, said signal identifying the modulator of said amino acid sequence.

58. The method according to claim 57, wherein said amino acid sequence has an amino acid sequence of: SEQ ID NO: 2.

- 15 59. The method according to claim 58, wherein a nucleic acid sequence that encodes said amino acid sequence is SEQ ID NO: 1.

60. A method of controlling an insect, comprising contacting an insect with an inhibitor identified by a method of identifying said inhibitor, wherein said method
- 20 comprises the steps of:
- a) contacting an amino acid sequence, or a host cell or host organism containing or expressing the amino acid sequence, with a test chemical, in such a way that a signal may be generated that is representative for the interaction between said test chemical and said the target; and optionally
- 25 b) detecting the signal that may thus be generated, said signal identifying the inhibitor of said amino acid sequence.

61. The method according to claim 60, wherein said aminio acid has an amino acid sequence of: SEQ ID NO: 2.

30

Chaguturu et al.
Docket No.: 60301-USA-PROV1

PATENT

62. The method according to claim 61, wherein a nucleic acid sequence that encodes said amino acid sequence is SEQ ID NO: 1.
- 5 63. A method of controlling an insect, comprising contacting an insect with the modulator of claim 19.
64. A method of controlling an insect, comprising contacting an insect with the modulator of claim 20.
- 10 65. A method of controlling an insect, comprising contacting an insect with the modulator of claim 21.
66. A method of controlling an insect, comprising contacting an insect with the modulator of claim 22.
- 15 67. A method of controlling an insect, comprising contacting an insect with the modulator of claim 23.
68. A method of controlling an insect, comprising contacting an insect with the modulator of claim 24.
- 20 69. A method of controlling an insect, comprising contacting an insect with the modulator of claim 43.
- 25 70. A method of controlling an insect, comprising contacting an insect with the modulator of claim 44.
71. A method of controlling an insect, comprising contacting an insect with the modulator of claim 49.
- 30

Chaguturu et al.
Docket No.: 60301-USA-PROV1

PATENT

72. A method of controlling an insect, comprising contacting an insect with the modulator of claim 50.
73. A method of controlling an insect, comprising contacting an insect with the
5 modulator of claim 51.
74. A method of controlling an insect, comprising contacting an insect with the modulator of claim 52.
- 10 75. A method of controlling an insect, comprising contacting an insect with the inhibitor of claim 53.
76. A method of controlling an insect, comprising contacting an insect with the inhibitor of claim 54.
15
77. A method of controlling an insect, comprising contacting an insect with the inhibitor of claim 55.
78. A method of controlling an insect, comprising contacting an insect with the
20 inhibitor of claim 56.

ABSTRACT

Novel nucleic acid sequences encoding *hemipteran* L-glutamate decarboxylases, and recombinant expressions and host cells comprising the same are disclosed. Isolated
5 *hemipteran* L-glutamate decarboxylases, host cells expressing *hemipteran* L-glutamate decarboxylases, methods of producing the *hemipteran* L-glutamate decarboxylases and antibodies specific for *hemipteran* L-glutamate decarboxylases are also disclosed. Methods of identifying modulators and/or inhibitors of *hemipteran* L-glutamate decarboxylases are disclosed. Compounds that can modulate and/or inhibit amino acid
10 sequences of the invention, compositions that contain such compounds, and to the use of such compounds in the preparation of such compositions are also disclosed.

SEQUENCE LISTING

<110> FMC Corporation
Allenza, Paul
5 Gilby, Susan
Wong, Victoria
Chen, Ruihua
Chargaturu, Rathnam

10 <120> Aphis gossypii glutamic acid decarboxylase
<130> 60301
<160> 2

15 <170> PatentIn version 3.1
<210> SEQ ID NO: 1
<211> 1936
20 <212> DNA
<213> Aphis gossypii

<400> SEQ ID NO: 1
25 ccactgcgtc acttcataa gtcttgatca tcgtctagcc accaacgaca cgacttactg 60
cogtctctgc agcgaaatac gcttccgaat aatccgatac agccaaccac cgtcgtgatg 120
aattctaagc ccgatggaca gcagtccaag tatcagctgt caaaggatac agctggactt 180
30 cgttcaacag atttattacc tcataatttg tccggacagg cacaaaccag agagtttctt 240
ttaaaagtcg ttgatattct agtagattac attgatgacg ttaatgatag aaacgaaaaa 300
gtattgcatt ttaagcaccc cgaagagatg ttacgactgc tacaattgga tattcccaac 360
35 gaagggtgtc cattacaaaa tttaatcgac gattgcagtc taacactcaa gcatcaagta 420
aaaacaggac atccaagatt tttcaaccag ctttcatgcg gtctagacat cgtgtccatg 480
40 gctggcgaat ggctgacggc gacggctaac acgaacatgt tcacctacga aatcgctcca 540
gtattttattc tcatggaaaa cgtgggtgta accaagatga gagaaatcat tgggtggaag 600
accggcgact caatttttgc tccaggtgga tcaatatcga atatgtacgc gtttttggcc 660
45 gcccgtcata aaatgttccc aggatacaag gaacaaggac tccactcgat caaaggacaa 720
ctgggtcatgt acacatcaaa ccaatcgcat tattcggtta agagttgtgc atcggtatgc 780
50 ggactaggaa ccgaaaattg tgtcgaagta cctagcgacg aaaggggccg catgatacct 840
tctgagctgg agcgccctcat attggaaaga aaatocaaag gccacatacc gtttttcgtc 900
tctgccactg caggcacgac tgttcttggg gcatttgatc caatcaacga cattgcggac 960
55 atttgcgaaa aatataagct gtggcttcac attgatgctg cctgggggtgg aggactgctt 1020
ctatctcgca agtaccgata tcccgtctg gctggcatcg aacgggctaa ctcagtgact 1080
60 tggaatccac acaaacttat gggcacccta ctccagtgt ccacaatata ttttcgagag 1140

Chaguturu et al.
Docket No.: 60301-USA-PROV1

PATENT

```

aatggaattt tgatcagctg caaccaaattg agcgcggaat acttattcat gcaagacaaa 1200
ctgtacgacg ttcaatacga cacaggcgac aaagttatac agtgtggtcg tcacaacgac 1260
5 gtgttcaagc tttggcttca atggcgcgcc aagggtaccg aagggttcga aaaacacatg 1320
gatcacttga tggaactcag tgaatatatg gtggagaaaa ttaaagcatc gccagacaaa 1380
tattatttac tccttgaacc ggaaatggtg aacgtcagtt tttggtacgt tccgaagcgc 1440
10 ttgcgaaaca ttccacattc tccgaaacga gcggaaagcc ttggcaagat cagcctatt 1500
ctgaaggcca aatgatgga agccggcacg ctgatggtag ggtatcagcc actaaacgag 1560
15 ataccgaact ttttccgaa cattatatcc agcgcgcggg tcaccaagga agacgttgac 1620
tttttgctgt ccgaacttga tcgcttgga caagacctct aaatcaggag gaaaagaaac 1680
gattaatgat aaatttcgct agtctctata atatatttag ttattttatt gtgttatgat 1740
20 tttgtagacg ctatgatcac gattcccggt caatggctat attcttgcca cgcgcctca 1800
ataataataa taataataat aagtagccta tgctgcgttt ataatacaga taatcgcata 1860
25 ataattaata atttttaatt ttaaataat acctatatat tataataggt gataagcgtt 1920
attccaaatc ttcctg 1936

30 <210> SEQ ID NO: 2
    <211> 514
    <212> PRT
    <213> aphis gossypii .

35 <400> SEQ ID NO: 2

Met Asn Ser Lys Pro Asp Gly Gln Gln Ser Lys Tyr Gln Leu Ser Lys
1          5          10          15

40 Asp Thr Ala Gly Leu Arg Ser Thr Asp Leu Leu Pro His Asn Leu Ser
          20          25          30

45 Gly Gln Ala Gln Thr Arg Glu Phe Leu Leu Lys Val Val Asp Ile Leu
          35          40          45

50 Val Asp Tyr Ile Asp Asp Val Asn Asp Arg Asn Glu Lys Val Leu His
          50          55          60

55 Phe Lys His Pro Glu Glu Met Leu Arg Leu Leu Gln Leu Asp Ile Pro
          65          70          75          80

Asn Glu Gly Val Pro Leu Gln Asn Leu Ile Asp Asp Cys Ser Leu Thr
          85          90          95

60 Leu Lys His Gln Val Lys Thr Gly His Pro Arg Phe Phe Asn Gln Leu

```


Chaguturu et al.
Docket No.: 60301-USA-PROVI

PATENT

	100	105	110
5	Ser Cys Gly Leu Asp Ile Val 115	Ser Met Ala Gly Glu Trp 120	Leu Thr Ala 125
10	Thr Ala Asn Thr Asn Met Phe 130	Thr Tyr Glu Ile Ala Pro 135	Val Phe Ile 140
15	Leu Met Glu Asn Val Val Leu Thr Lys Met Arg Glu Ile Ile Gly Trp 145	150	155
20	Lys Thr Gly Asp Ser Ile Phe Ala Pro Gly Gly Ser Ile Ser Asn Met 165	170	175
25	Tyr Ala Phe Leu Ala Ala Arg His Lys Met Phe Pro Gly Tyr Lys Glu 180	185	190
30	Gln Gly Leu His Ser Ile Lys Gly Gln Leu Val Met Tyr Thr Ser Asn 195	200	205
35	Gln Ser His Tyr Ser Val Lys Ser Cys Ala Ser Val Cys Gly Leu Gly 210	215	220
40	Thr Glu Asn Cys Val Glu Val Pro Ser Asp Glu Arg Gly Arg Met Ile 225	230	235
45	Pro Ser Glu Leu Glu Arg Leu Ile Leu Glu Arg Lys Ser Lys Gly His 245	250	255
50	Ile Pro Phe Phe Val Ser Ala Thr Ala Gly Thr Thr Val Leu Gly Ala 260	265	270
55	Phe Asp Pro Ile Asn Asp Ile Ala Asp Ile Cys Glu Lys Tyr Lys Leu 275	280	285
60	Trp Leu His Ile Asp Ala Ala Trp Gly Gly Gly Leu Leu Leu Ser Arg 290	295	300
	Lys Tyr Arg Tyr Pro Arg Leu Ala Gly Ile Glu Arg Ala Asn Ser Val 305	310	315
	Thr Trp Asn Pro His Lys Leu Met Gly Thr Leu Leu Gln Cys Ser Thr 325	330	335
	Ile His Phe Arg Glu Asn Gly Ile Leu Ile Ser Cys Asn Gln Met Ser 340	345	350

PATENT

- 46 -

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox